{"id":6539,"date":"2021-03-12T17:09:25","date_gmt":"2021-03-13T01:09:25","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=6539"},"modified":"2021-03-12T17:09:25","modified_gmt":"2021-03-13T01:09:25","slug":"novavax-confirms-high-levels-of-efficacy-against-original-and-variant-covid-19-strains-in-united-kingdom-and-south-africa-trials","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/12\/novavax-confirms-high-levels-of-efficacy-against-original-and-variant-covid-19-strains-in-united-kingdom-and-south-africa-trials\/","title":{"rendered":"Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials"},"content":{"rendered":"<ul>\n<li><i>[Press release, not peer-reviewed]<\/i> A Phase 3 trial of the Novavax vaccine (NVX\u2011CoV2373) in the UK indicated an efficacy of 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain. The company also announced final results of its Phase 2b trial conducted in South Africa, with an efficacy of 55.4% among HIV-negative trial participants in a region where the vast majority of strains are B.1.351 variants. Across both trials, NVX-CoV2373 demonstrated 100% protection against severe disease, including all hospitalization and death.<\/li>\n<\/ul>\n<p><i>Novavax.\u00a0(Mar 11, 2021). Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials. Downloaded Mar 11 from <\/i><a href=\"https:\/\/ir.novavax.com\/news-releases\/news-release-details\/novavax-confirms-high-levels-efficacy-against-original-and\">https:\/\/ir.novavax.com\/news-releases\/news-release-details\/novavax-confirms-high-levels-efficacy-against-original-and<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Press release, not peer-reviewed] A Phase 3 trial of the Novavax vaccine (NVX\u2011CoV2373) in the UK indicated an efficacy of 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain. The company also announced final results of its Phase 2b trial conducted in South Africa, with an efficacy of 55.4% among HIV-negative&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/12\/novavax-confirms-high-levels-of-efficacy-against-original-and-variant-covid-19-strains-in-united-kingdom-and-south-africa-trials\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-6539","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6539","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=6539"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6539\/revisions"}],"predecessor-version":[{"id":6540,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6539\/revisions\/6540"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=6539"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=6539"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=6539"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=6539"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}